Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Beam Therapeutics

Beam Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Threshold

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance.

Investors Business Daily

Beam Therapeutics Sees Relative Strength Rating Rise To 72

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Beam Therapeutics Stock Earns RS Rating Jump To 85

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance.

Investors Business Daily

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Barchart

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement

Beam Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Investors Business Daily

Erasing or replacing errors in a patient's genetic code can treat and cure some genetic diseases

Genetic diseases can have devastating consequences for the people who inherit them. In recent years, scientists have found that there are human genetic diseases that might be treatable, and perhaps even curable, through gene editing. Gene editing is the process by which sections of a person’s DNA are altered. Commonly…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.